Mereo Biopharma Group Plc ADR (MREO) Stock Price, Quote & News

Company Profile

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteope...

Industry: Biotechnology

Sector: Healthcare

Phone: 44 33 3023 7300

Website: www.mereobiopharma.com

Address:

One Cavendish Place, 4th Floor, London, United Kingdom

LDT79 Aug. 19 at 1:31 PM

$MREO fucking short sellers motherfuckers!11

0 · Reply

LDT79 Aug. 19 at 1:20 PM

$MREO well.. at least no R/S for now but can Denise turn the ship around?

0 · Reply

TragicRain Aug. 19 at 12:40 PM

$MREO - dont know how much it will help but... '"On August 18, 2026, the Company received a second notice (the “Second Notice”) from the Staff indicating that, while the Company has not yet regained compliance with the Bid Price Requirement, the Company is eligible for an additional 180 calendar day period, or until February 16, 2027 (the “Second Compliance Period”), to regain compliance. "

2 · Reply

GamblingFerret Aug. 19 at 12:07 PM

$MREO There we go: https://mereobiopharma.gcs-web.com/static-files/a7d8d99a-eed6-4882-ba2e-4a3f960990db

0 · Reply

GamblingFerret Aug. 19 at 8:55 AM

$MREO Interesting thought: With opt-in, Sentynl gives Alvelestat a clear value today: - Opt in fee est. 10 Mio - Upfront & R&D payment 40 Mio - Phase 3 financing est. 100-150 Mio As Mereo keeps rights outside US, this gives immediate external asset valuation worth between 150-200 Mio (Worldwide ex-us) - today! All further developments create additional values. This is worth more than 1 dollar alone, with clear upsides in terms of positive development. As you, I am desperately waiting for the Nasdaq prolongation. But the opt-in will be a game changer for Mereos valuation, hopefully followed by postive agency feedback on Setrusumab path forward.

0 · Reply

LDT79 Aug. 18 at 2:35 PM

$MREO no buyers yet - Denise has disappointed once again?

0 · Reply

theSmokingBuzzard Aug. 17 at 10:38 PM

$MREO Guess we’re going otc

2 · Reply

ZK73 Aug. 17 at 3:24 PM

$MREO expecting above 0.9 by EOY

1 · Reply

LDT79 Aug. 17 at 1:28 PM

$MREO crickets? Today is last day of compliance?

2 · Reply

Coco63 Aug. 17 at 12:24 PM

$IMMP The probability of a buyout by Merck is between 40% and 60%. The purchase price would likely range from €1.5 billion to €2 billion. I’m placing my bets for the end of the year. Immutep’s annual report, due next week, will provide an opportunity to update the status of ongoing clinical trials, and the stock could see a strong upward surge. $MRK $CAPR $GOSS $KPTI $MREO $NVO $LLY $NBIS $FAMI $DFSC $SPCX $XPON $SRPT $AAOI $AMZN $GYGY $NVDA $AAPL $IPST

1 · Reply